Literature DB >> 27623139

Variability of Serum Thyroglobulin Levels in Post- Thyroidectomy Patients with Well-Differentiated Thyroid Cancer: the ATA Guidelines.

Frieda Silva1, Ralph J Martin1, Jannette Figueroa1, Fernando Rincón1, Diego Román1.   

Abstract

OBJECTIVE: Evaluate the variability of stimulated serum thyroglobulin (Tg) levels in post-thyroidectomy patients with well-differentiated thyroid cancer (WDTC) and determine the frequency of undetectable Tg in patients with evidence of functional thyroid tissue after a 131-I whole-body scan (WBS).
METHODS: A retrospective record review of patients with WDTC referred to our clinic from 1990 to 2010. Demographic data, histology, staging, imaging studies, stimulated Tg values, and the presence if applicable of Tg antibodies (TgAb) were documented. The images of whole-body radioiodine scans were reviewed to assess the extent of functional thyroid tissue.
RESULTS: A total of 142 cases were evaluated with 417 studies. There were 112 women and 30 men; the median age was 47 years. The tumor histologies included 97 papillary (4 had the Hurthle cell variant), 33 papillary-follicular tumor, and 12 follicular tumors; 7 were multifocal. ATA classification was used; groups were divided into low (55%) and intermediate-high risk (45%). The final analysis comprised 84 patients, having among them 170 studies that included Tg values in their records. The cut-off value for Tg was 2.0 ng/ml, and for TgAb, it was 20 IU/ml or more. Residual functional tissue was present in 105 (62%) cases. Discordant Tg results were found in 55% of the low-risk patients; of those, only 3 had TgAb. In the intermediate- and high-risk group, 47% had discordant results; 2 cases had TgAb.
CONCLUSION: The variability of the Tg levels and the high frequency of discordant results (positive WBSs with undectable Tg levels) bring into question the standard recommendation of conservative management for low-risk patients. Follow-ups should include a Tg assay and imaging studies.

Entities:  

Keywords:  Low-risk thyroid cancer; Serum Thyroglobulin; Thyroid Cancer

Mesh:

Substances:

Year:  2016        PMID: 27623139      PMCID: PMC5295135     

Source DB:  PubMed          Journal:  P R Health Sci J        ISSN: 0738-0658            Impact factor:   0.705


  12 in total

Review 1.  Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer.

Authors:  E L Mazzaferri; R T Kloos
Journal:  J Clin Endocrinol Metab       Date:  2001-04       Impact factor: 5.958

Review 2.  Serum thyroglobulin measurement in the follow-up of patients treated for differentiated thyroid cancer.

Authors:  G Zucchelli; A Iervasi; M Ferdeghini; G Iervasi
Journal:  Q J Nucl Med Mol Imaging       Date:  2009-10       Impact factor: 2.346

3.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

4.  Papillary thyroid microcarcinoma: proposal of treatment based on histological prognostic factors evaluation.

Authors:  Guglielmo Ardito; Nicola Avenia; Erica Giustozzi; Massimo Salvatori; Guido Fadda; Francesco Ardito; Luca Revelli
Journal:  Ann Ital Chir       Date:  2014 Jan-Feb       Impact factor: 0.766

Review 5.  Update on recent developments in the therapy of differentiated thyroid cancer.

Authors:  Marcus Middendorp; Frank Grünwald
Journal:  Semin Nucl Med       Date:  2010-03       Impact factor: 4.446

Review 6.  Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer.

Authors:  Peter Lind; Susanne Kohlfürst
Journal:  Semin Nucl Med       Date:  2006-07       Impact factor: 4.446

7.  Aggressive papillary thyroid microcarcinoma: prognostic factors and therapeutic strategy.

Authors:  Guglielmo Ardito; Luca Revelli; Erika Giustozzi; Massimo Salvatori; Guido Fadda; Francesco Ardito; Nicola Avenia; Alice Ferretti; Lucia Rampin; Sotirios Chondrogiannis; Patrick M Colletti; Domenico Rubello
Journal:  Clin Nucl Med       Date:  2013-01       Impact factor: 7.794

8.  Relationship between tumor burden and serum thyroglobulin level in patients with papillary and follicular thyroid carcinoma.

Authors:  Anne Bachelot; Anne Françoise Cailleux; Michele Klain; Eric Baudin; Marcel Ricard; Nicolas Bellon; Bernard Caillou; Jean Paul Travagli; Martin Schlumberger
Journal:  Thyroid       Date:  2002-08       Impact factor: 6.568

9.  The follow-up of patients with differentiated thyroid cancer and undetectable thyroglobulin (Tg) and Tg antibodies during ablation.

Authors:  Ha T T Phan; Pieter L Jager; Jacqueline E van der Wal; Wim J Sluiter; John T M Plukker; Rudi A J O Dierckx; Bruce H R Wolffenbuttel; Thera P Links
Journal:  Eur J Endocrinol       Date:  2008-01       Impact factor: 6.664

10.  Recurrent/metastatic thyroid carcinomas false negative for serum thyroglobulin but positive by posttherapy I-131 whole body scans.

Authors:  Eun-Kyung Park; June-Key Chung; Il Han Lim; Do Joon Park; Dong Soo Lee; Myung Chul Lee; Bo Youn Cho
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-09-09       Impact factor: 9.236

View more
  1 in total

1.  Residual Thyroid Tissue on Postoperative Diagnostic 131 I Radioactive Whole-Body Scan After Surgery in Differentiated Thyroid Cancer: A Tertiary Referral Centre Experience.

Authors:  Rachana Prasad; Vishal Rao; Anand Subash; Kinjal Shankar Majumdar; Piyush Sinha; Kumar Kallur; Ravi C Nayar
Journal:  Indian J Surg Oncol       Date:  2021-06-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.